13F HOLDINGS REPORT (Amended)
Decheng Capital Management III (Cayman), LLC
Quarter ended Q4 2023 · Filed December 12, 2023 · Accession 0001104659-23-125265
Total Value
$299.6M
Positions
26
Other Managers
0
Confidential Omitted
No
Holdings (26)
| # | Issuer | Ticker / CUSIP | Shares | Value | % of Filing |
|---|---|---|---|---|---|
| 1 | Alpine Immune Sciences, Inc. | 02083G100 | 6,708,288 | $76.8M | 25.63% |
| 2 | Zentalis Pharmaceuticals Inc. | ZNTL | 2,099,583 | $42.1M | 14.06% |
| 3 | Aura Biosciences, Inc. | AURA | 1,163,123 | $18.2M | 6.09% |
| 4 | ROIVANT SCIENCES LTD | ROIV | 1,459,700 | $17.0M | 5.69% |
| 5 | ACELYRIN INC(NSM) | 00445A100 | 1,548,317 | $15.7M | 5.26% |
| 6 | Arcus Biosciences, Inc | RCUS | 869,790 | $15.6M | 5.21% |
| 7 | 10x Genomics, Inc. | TXG | 359,554 | $14.8M | 4.95% |
| 8 | Argenx SE | ARGX | 27,429 | $13.5M | 4.50% |
| 9 | Pacific Biosciences of California, Inc. | 69404D108 | 1,463,872 | $12.2M | 4.08% |
| 10 | Illumnia, Inc. | ILMN | 80,859 | $11.1M | 3.70% |
| 11 | LANTHEUS HOLDINGS INC(NMS) | LNTH | 142,196 | $9.9M | 3.30% |
| 12 | Horizon Therapeutics PLC | G46188101 | 78,900 | $9.1M | 3.05% |
| 13 | PHATHOM PHARMACEUTICALS INC | PHAT | 850,000 | $8.8M | 2.94% |
| 14 | IMMUNOGEN INC | 45253H101 | 415,880 | $6.6M | 2.20% |
| 15 | SEAGEN INC | SE | 23,014 | $4.9M | 1.63% |
| 16 | Cue Health Inc. | 229790100 | 8,980,909 | $4.0M | 1.32% |
| 17 | BeyondSpring Inc. | BYSI | 4,958,143 | $4.0M | 1.32% |
| 18 | Terns Pharmaceuticals, Inc. | TERN | 714,285 | $3.6M | 1.20% |
| 19 | Equillium Inc. | EQ | 4,447,308 | $3.3M | 1.10% |
| 20 | Aadi Bioscience, Inc. | WHWK | 526,329 | $2.5M | 0.85% |
| 21 | AtriCure Inc. | ATRC | 46,259 | $2.0M | 0.68% |
| 22 | Scynexis Inc. | SCYX | 555,555 | $1.3M | 0.42% |
| 23 | Mersana Therapeutics, Inc. | 59045L106 | 904,268 | $1.1M | 0.38% |
| 24 | Pyxis Oncology, Inc (formerly Apexigen) | PYXS | 326,810 | $650,352 | 0.22% |
| 25 | GeneDx Holdings Corp. | WGSWW | 103,604 | $377,118 | 0.13% |
| 26 | Adicet Bio, Inc. | ACET | 200,201 | $274,275 | 0.09% |